The performance failure is an inability to excite the market....

The performance failure is an inability to excite the market.
Prior to the AIPAC results period they should have bought in some PR people with speccy biotech experience and done some serious work on how they were going to shift the messaging as the company moves into a new phase. It’s not a hard sell given what they are doing. Maybe that is starting to happen, we’ll see. But it’s an uphill battle when it doesn’t come naturally to the CEO or company culture.

I’ll give them the benefit of the doubt for now but I’d like to see a new approach develop over the next six months. It’s very important particularly in the light of the likely first LAG3 compound approval in March. Imm needs to maximize its exposure around this time and seize the moment.